Eledon Pharmaceuticals to Present Long-Term Data on Tegoprubart for Kidney Transplant Rejection
Event summary
- Eledon Pharmaceuticals will present Phase 2 BESTOW trial data on tegoprubart at the International Congress of The Transplantation Society on September 22, 2026.
- The presentation will focus on long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection.
- Presenter Andrew Adams, M.D., Ph.D., is Professor of Surgery at the University of Minnesota and Executive Medical Director of Solid Organ Transplant Service Line at M Health Fairview.
- Tegoprubart is an anti-CD40L antibody targeting immune modulation for transplant rejection and other conditions.
The big picture
Eledon's presentation at the International Congress of The Transplantation Society underscores the growing interest in next-generation immunosuppressants. The focus on long-term safety and efficacy data for tegoprubart comes as the transplant medicine field seeks more targeted and less toxic therapies. Success in this space could position Eledon as a key player in immune modulation, particularly if tegoprubart demonstrates sustained benefits over existing treatments.
What we're watching
- Clinical Validation
- How the long-term data on tegoprubart will impact its regulatory and commercial prospects in kidney transplantation.
- Market Differentiation
- Whether Eledon can position tegoprubart as a superior alternative to existing immunosuppressant therapies.
- Pipeline Expansion
- The pace at which Eledon advances tegoprubart into other indications like ALS and xenotransplantation.
Related topics